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Abstract
Objective: The aim of this study was to describe treatment outcomes for multi-drug resistant tuberculosis (MDR-TB)
outpatients on a standardized regimen in Nepal.
Methodology: Data on pulmonary MDR-TB patients enrolled for treatment in the Green Light Committee-approved
National Programme between 15 September 2005 and 15 September 2006 were studied. Standardized regimen was used
(8Z-Km-Ofx-Eto-Cs/16Z-Ofx-Eto-Cs) for a maximum of 32 months and follow-up was by smear and culture. Drug
susceptibility testing (DST) results were not used to modify the treatment regimen. MDR-TB therapy was delivered in
outpatient facilities for the whole course of treatment. Multivariable analysis was used to explain bacteriological cure as a
function of sex, age, initial body weight, history of previous treatment and the region of report.
Principal Findings: In the first 12-months, 175 laboratory-confirmed MDR-TB cases (62% males) had outcomes reported.
Most cases had failed a Category 2 first-line regimen (87%) or a Category 1 regimen (6%), 2% were previously untreated
contacts of MDR-TB cases and 5% were unspecified. Cure was reported among 70% of patients (range 38%–93% by Region),
8% died, 5% failed treatment, and 17% defaulted. Unfavorable outcomes were not correlated to the number of resistant
drugs at baseline DST. Cases who died had a lower mean body weight than those surviving (40.3 kg vs 47.2 kg, p,0.05).
Default was significantly higher in two regions [Eastern OR=6.2; 95%CL2.0-18.9; Far West OR=5.0; 95%CL1.0-24.3]. At
logistic regression, cure was inversely associated with body weight ,36 kg [Adj.OR=0.1; 95%CL0.0-0.3; ref. 55–75 kg] and
treatment in the Eastern region [Adj.OR=0.1; 95%CL0.0-0.4; ref. Central region].
Conclusions: The implementation of an ambulatory-based treatment programme for MDR-TB based on a fully standardized
regimen can yield high cure rates even in resource-limited settings. The determinants of unfavorable outcome should be
investigated thoroughly to maximize likelihood of successful treatment.
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Introduction
The emergence of strains of tuberculosis (TB) that resist drugs
poses a potentially devastating threat to TB control globally [1,2].
Forms of TB resistant to the most effective anti-TB medication,
including multidrug-resistant TB (MDR-TB, defined as TB
resistant to at least isoniazid and rifampicin, the two most
powerful anti-TB drugs) [3] and extensively drug-resistant TB
(XDR-TB, defined as MDR-TB plus resistance to at least
fluoroquinolones and one of the second-line injectable drugs -
amikacin, kanamycin or capreomycin) [4], have been identified in
many parts of the world. Drug-resistant TB is associated with
inadequate treatment, resulting from too few or low-quality drugs,
non-compliance on part of the patient, and conditions which
favour TB transmission. These factors are particularly common in
resource-limited settings.
Treatment of MDR-TB is resource intensive and lasts for 24
months or more, requiring a combination of second-line drugs that
are more expensive, less effective and more toxic than those used
in standard first-line treatment regimens [3,5]. The control of
drug-resistant TB requires a strong health infrastructure to ensure
prompt diagnosis, timely delivery of effective treatment, and
interventions to reduce transmission, while monitoring the
development of the epidemic through surveillance activities [3].
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8313In 2000, to address the emergence of MDR-TB, the World Health
Organization (WHO) and the STOP TB Partnership formed a
subgroup called the Green Light Committee (GLC) Initiative
whose mission is to ensure effective treatment of patients with
drug-resistant TB in resource-limited settings in accordance with
WHO guidelines [6]. Since its establishment the GLC has
approved second-line treatment for over 50,000 MDR-TB
patients in more than 60 countries [7]. One of these countries is
Nepal, where a GLC-approved programme started treating
patients in 2005.
InNepal TB is a majorpublichealth issue.In2007, there were
an estimated 48,766 incident TB cases (173/100,000) [8].
MDR-TB occurred among 2.9% of previously un-treated TB
cases and 11.7% of previously treated [1,9]. In 2001–2, 88% of
cases in whom a retreatment regimen (‘‘Category 2’’) failed as
well as 24% in whom regimen for previously untreated
(‘‘Category 1’’) failed were found to have MDR-TB [9]. To
address this challenge, National TB Programme designed a
standardized retreatment regimen for MDR-TB with second-
line drugs based on surveyed drug resistance patterns in the
country [10]. Patients were eligible for such regimen for MDR-
TB if they failed a retreatment regimen with first line drugs
(ahead of laboratory confirmation) or if they were confirmed
MDR-TB, while Category 1 failures and smear positive contacts
of MDR-TB patients would be tested for DST before start of
MDR-TB treatment. Drugs to counter and prevent side-effects
were made available free-of-charge to patients. NTP staff were
t r a i n e dt om a n a g et h ep a t i e n t sa n dr e c o r dd a t af o rt h e
programme. Treatment was delivered under direct observation
on an ambulatory basis through a decentralized network of
clinics. By June 2009, 612 patients had been started on
treatment and 10 treatment centres and 34 sub-centers were in
use throughout the country (Figure 1). The Central region -
which includes the capital Kathmandu - accounts for more than
half of the patients enrolled and has been the longest standing
DOTS-Plus centre.
In this article we describe the outcomes of patients with
laboratory confirmed MDR-TB who received treatment during
the first 12-months of the MDR-TB treatment programme.
Materials and Methods
Study Population
Between 15 September 2005 and 15 September 2006 a total of
224 patients were enrolled in the GLC-approved treatment
programme in Nepal to receive standardized, second-line drug
therapy for pulmonary MDR-TB. Of these, 175 patients with
confirmed MDR-TB who began treatment in this period were
retained for the study (Table 1). Exclusions included eligible
patients who did not start treatment (2 cases), patients with no
culture results reported after treatment initiation (2 cases), and
those with negative culture results at the beginning and throughout
the treatment period (18 cases). Of the 202 patients with culture
positive TB, 8 were found to have Nontuberculous mycobacteria
(NTM). Of the 194 patients with disease caused by Mycobacterium
tuberculosis we excluded those with no baseline drug susceptibility
Figure 1. MDR-TB treatment centers and sub-centers in Nepal. Footnote Figure 1: In 2005–2006, not all the health centres were functioning.
The 175 cases included in this study were under care at 17 clinics (Bhaktapur, Bheri, Bir, Genetup, Haraicha, HelpHand, INF_Banke, KohalpurMC,
Mahakali, Mangalbare, NATA, NMC, NTC, Patan, RTC, Stupa, and TUTH).
doi:10.1371/journal.pone.0008313.g001
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DST results did not meet the definition of MDR-TB (confirmed
susceptibility to either isoniazid and rifampicin) (13 cases).
Patients were categorized according to the registration groups
used by the Nepal NTP: Category 2 treatment failure, Category 1
treatment failure with DST confirmed MDR-TB, and previously
untreated MDR-TB family contact. Cases for whom the
registration group was not known were retained in the analysis.
This analysis was carried out retrospectively and involved basic
data collected on a routine basis within the NTP services to
regularly monitor the performance of the MDR-TB treatment
program. The data were analyzed anonymously. The implemen-
tation of such program activity, including the monitoring and
evaluation system, is a routine and regular component of the NTP
activities and approved by the Ministry of Health and Population of
Nepal; therefore no ethical approval was required for this analysis.
Laboratory Diagnosis and Bacteriological Follow-Up
Diagnosis of MDR-TB was performed at GENETUP TB-
laboratory which functions as the National Reference Laboratory
in the capital Kathmandu using the indirect proportion method on
Lo ¨wenstein-Jensen medium. The external quality control for this
laboratory is organized and performed by the Supranational
Laboratory in Gauting, Germany since 1994 using proportion
method. At least one positive culture per patient was also tested
using the GenoTypeH MTBDR plus test of Hain Lifescience. All
discrepant results were retested in both systems. If the identifica-
tion of strains in the GenoTypeH MTBDR plus test revealed not a
M. tuberculosis complex, the GenoTypeH Mycobacteria CM test was
applied additionally to identify the NTM. In the study period DST
was available for the following four first-line drugs: rifampicin,
isoniazid, streptomycin, and ethambutol. DST for pyrazinamide
and second-line drugs was not available in the country at the time
of this study. In this article, DST was considered as baseline if the
sample (sputum) was obtained from a patient within a period of 60
days prior to starting treatment until 40 days after start.
Laboratory follow-up to monitor treatment progress is con-
ducted by sputum smear microscopy and culture conducted
monthly during the first eight months of treatment (or 12 months if
intensive phase was extended) and then every two months till the
end of treatment.
Treatment Scheme and Delivery
All patients enrolled received the same standardized treatment
regimen for MDR-TB. Individual DST results were not used to
modify the treatment regimen. The regimen was designed based
on the results of DST to first- and second-line anti-TB drugs
conducted within the context of a nationwide drug resistance
survey, as described elsewhere [9,10], and in accordance with
experts’ opinion from the GLC. In addition the database of
GENETUP TB-laboratory was reviewed to inform the decision
making process. The regimen is composed of five drugs
(pyrazinamide, kanamycin, ofloxacin, ethionamide, and cycloser-
ine) in the intensive phase, which usually lasts eight months but is
extended to twelve months if the patient is smear- or culture-
positive at six months (8Z-Km-Ofx-Eto-Cs/16Z-Ofx-Eto-Cs). It
should be noted that drugs were selected in accordance to the
2003 WHO guidelines for TB treatment [11]. At that time
ofloxacin was the recommended fluoroquinolone. Cycloserine was
selected instead of PAS because felt to cause less serious adverse
events and consequently be more manageable in a fully
ambulatory-based treatment program. In addition, at that time,
PAS was only available through the GLC mechanism in format
that required refrigeration and this was felt a serious barrier for its
use in Nepal.
The duration of the initial phase was also discussed with the
GLC. In Nepal is was decided to prolong the initial phase to 8
months to allow the administration of kanamycin over a longer
period. It was felt that to provide the full dosage of daily 6 months
kanamycin over a slightly longer period (4 month daily and 4
months thrice weekly) - 8 months in total, might reduce the toxic
effects that are usually seen between 4 to 6 months, and extend the
time of impact on the overall regimen.
The same drugs, excepting kanamycin, are used in the
continuation phase, which usually lasts 16 months but may be
extended by up to 8 months if the patient’s culture converts to
negative only between 12 and 18 months of treatment. Treatment
is available in two dosages according to the weight of the patient at
the beginning of treatment (up to 50 kg, .50 kg). The weight
categories were carefully worked out using the spread of actual
weights of a large sample of previously treated TB patients, and
showed to work well in practice. Weight cut-off were similar to
those used in another study in the same geographical area [12].
Table 1. Selection of the study population.
Enrolled between 15 September 2005 and 15
September 2006
R 224 patients R 2 patients never started on treatment
Q
Treated R 222 patients R 18 culture negative
QR 2 culture contaminated
With culture positive results R 202 patients R 5 M.intracellulare
R 2 M.fortuitum
QR 1 M.avium
Confirmed M.tb R 194 patients R 6 cases with DST on specimens taken .60 days
before or .40 days after start of treatment
R 5 rifampicin sensitive and isoniazid resistant
QR 8 rifampicin and isoniazid sensitive
Confirmed MDR-TB R 175 patients
doi:10.1371/journal.pone.0008313.t001
Treatment of MDR-TB in Nepal
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8313Treatment is delivered daily at the clinic. Support during
treatment is guaranteed by the presence of a treatment support
person nominated by the patient. A gastroprotective agent
(ranitidine) is also taken daily during the course of treatment to
decrease side effects. Treatment of minor adverse reactions with
symptomatic drugs as well as admission to hospital for severe side
effects are free of costs for the patients.
An active defaulter tracing system is in place and implemented
locally by the clinics with support and supervision from the District
TB/Leprosy Officers.
Data Recording and Analysis
Patient data are kept peripherally on treatment cards, key
outcome and treatment information transferred to district MDR-
TB registers and from these reported in aggregated quarterly
reports. Data from all the district registers is transferred to the
national MDR-TB treatment register, which is kept and updated
at the National Tuberculosis Centre (NTC) in Kathmandu. This
includes demographic information, initial body weight, patient
category based on previous treatment, treatment starting date,
bacteriology and outcome (dated). Information on socioeconomic
background, co-morbidities, or compliance with treatment was not
available from this source. An electronic register based on Open
Medical Record System (openmrs.org/wiki/Mdrtb_Module) was
installed for use at the NTC in October-November 2008 and
updated retrospectively with data from patients started in the
national MDR-TB treatment programme since 2005.
After cleaning the data were analyzed using the Stata SE/10.0
(Texas, US, 2007) and the Statcalc function of EpiInfo version 6
(CDC). Chi-squared test was used to identify significant associa-
tions (p,0.05) between categorical variables and outcomes and to
test linear trend. Strength of association is shown as crude odds
ratios with their corresponding 95% confidence limits. Two
sample t-test was used to explore associations between continuous
variables (age and body weight) and cure. A logistic regression
model was built to analyse cure as a function of sex, age, initial
body weight, previous treatment history, and the region where the
patient was treated.
Results
A total of 175 confirmed pulmonary MDR-TB patients were
enrolled in the national MDR-TB treatment programme in the
study period (Table 2). More than one half of patients were enrolled
in the central region of Nepal surrounding the capital. Sixty-two
percent of patients were male. Their median age was 30 years, and
84% of MDR-TB patients were aged between 20–50 years. No
significant difference in age was noted between the sexes. At the
time of enrolment, the patients’ median weight was 46 kg (5 kg
higher in males than females, p,0.05), with 129 (74%) patients
weighing up to 50 kg, and therefore receiving the lower dosage of
treatment. Sixteen patients (9%) weighed less than 36 kg at the time
of treatment start. Most patients were failures of Category 2
treatment (87%). All, but one, patients were smear-positive.
A full description of the resistance patterns to first-line anti-TB
drugs at baseline DST is given in Table 3. Of the 175 MDR-TB
Table 2. Characteristics of the study population.
Variable Male (N=108) Female (N=67) All sexes (N=175)
Age (y)
Mean (SD) 35.4 (12.9) 30.8 (11.4) 33.6 (12.5)
Median (IQR) 31.5 (20.5) 28 (12) 30 (18)
Body weight (kg)
Mean (SD) 48.6 (9.1) 43.6 (8.5) 46.7 (9.2)
Median (IQR) 47.5 (12) 42 (12) 46 (11)
Region N % N % N %
Eastern 12 11% 9 13% 21 12%
Central 68 63% 43 64% 111 63%
Western 12 11% 8 12% 20 11%
Mid-western 11 10% 4 6% 15 9%
Far-western 5 5% 3 4% 8 5%
Previous history
Category 2 failure 97 90% 56 84% 153 87%
Category 1 failure 6 6% 4 6% 10 6%
New case 1 1% 2 3% 3 2%
Not specified 4 4% 5 7% 9 5%
SD=Standard Deviation; IQR=Inter Quartile Range.
doi:10.1371/journal.pone.0008313.t002
Table 3. Resistance to first-line anti-TB drugs at baseline DST.
Drugs No. of patients % of patients
Isoniazid, Rifampicin 5 2.9
Isoniazid, Rifampicin, Streptomycin 31 17.7
Isoniazid, Rifampicin, Ethambutol 11 6.3
Isoniazid, Rifampicin, Streptomycin.,
Ethambutol
128 73.1
Total MDR 175 100
doi:10.1371/journal.pone.0008313.t003
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first-line drugs, 42 (24.0%) were infected with strains resistant to 3
first-line drugs, and 128 (73.1%) were infected with strains
resistant to all 4 first-line drugs tested.
Most patients have been cured (123, 70%), 14 patients died
(8%), 29 patients defaulted (17%), and nine patients failed (5%)
(Figure 2). No statistically significant difference in the number of
resistant drugs at baseline DST was found between patients who
became cured and those who experienced an unfavorable
treatment outcome (treatment failure, death, or default). The
proportion cured varied substantially by region. Default accounted
for much of the regional variation, with low default in the Central
region (76% cure) and none in the mid-West (93% cure). The
Eastern region had the lowest cure (38%) as a result of the highest
proportion of patients defaulting and dying. At bivariate analysis,
default was found to be associated with two regions with highest
default [Eastern OR=6.2; 95%CL2.0-18.9; Far West OR=5.0;
95%CL1.0-24.3]. Cases who died had a lower mean body weight
than those surviving (40.3 kg vs 47.2 kg, p,0.05; data not shown).
One third of deaths and defaults happened within 2 months of
enrolment, following which the occurrence of both outcomes was
more or less constant throughout the remaining period of
treatment (Figure 3).
The median duration of bacteriological monitoring and of
treatment of cured cases was 730 days (range: 554–815 days, data
not shown). Among the 123 who were cured, 112 (91%)
experienced a durable sputum-smear conversion to negative
within the first six months after treatment start. Patients who
failed to be cured through the programme were treated for a
median duration of 721 days (range: 404–959 days). Of the 14
patients who died, one converted to negative at month three and
one at month seven after treatment while 12 patients were culture
positive at the time of death. Adverse events recorded during
treatment of this cohort of patients are presented in Table 4.
Figure 2. Treatment outcomes for MDR-TB cases by region, Nepal, 2005–2006.
doi:10.1371/journal.pone.0008313.g002
Figure 3. Months till death (N=14, thick line) or default (N=29, dotted line) for MDR-TB cases, Nepal, 2005–2006.
doi:10.1371/journal.pone.0008313.g003
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ship between cure and initial body weight (p=0.001). In the
Eastern region, cure was significantly lower than in the Central
(OR=5.1, 95%CL1.8 - 14.2) and Mid-western (OR=22.8,
95%CL1.5 - 340.0) regions. The same associations with body
weight and with region became stronger after adjustment in the
multivariable model (Table 5). No significant associations were
otherwise detected with sex, age-group and between the four
different treatment history categories.
Discussion
In this manuscript we describe the performance of an MDR-TB
treatment program in a resource-limited setting designed around
two main elements: a) integration of MDR-TB management in an
existing ambulatory-based TB care delivery system; b) utilization of
a fullystandardizedtreatmentregimen,i.e.DSTresultsarenotused
to modify treatment regimens. To our knowledge the large majority
of studies describing ambulatory- or community-based approaches
to MDR-TB treatment adopt individualized treatment regimens,
i.e. patients are offered an empiric treatment regimen which is
tailored to the resistance patterns of the infecting strain as soon as
DST results became available. Vast experience from Peru shows
that community-based treatment for MDR-TB and even XDR-TB
is feasible and can yield high cure rates [13,14,15]. The findings of
our study go on the same direction: integrating MDR-TB treatment
in a fully ambulatory-based TB care delivery system in resource-
limitedsettings is possible with very good treatmentoutcome results.
Compared to Peru the experience from Nepal shows us something
additional: a standardized treatment regimen for MDR-TB, when
designed based on good drug resistance surveillance data, can be
successfully delivered in a resource-limited setting through an
ambulatory-based system without the need of tailoring it to
individual DST results. The cure rates documented in our study
are quite high (70%) and in line with those reported in hospital-
based care delivery systems or using individualized treatment
regimens based on DST results [5]. Previous experiences have
shown the feasibility of using fully standardized treatment regimens
for MDR-TB but, in most circumstances, patients were hospitalized
at least during the initial phase of treatment. In Bangladesh, for
example, cure rates of 69% among MDR-TB patients were
achieved using a fully standardized treatment regimen, but patients
wereasked to stay in hospitals for the first three months of treatment
[12]. A fully standardized treatment regimen for MDR-TB was also
used in the Republic of Korea; in that circumstance the therapy was
self administered and treatment outcomes were very poor [16].
In Peru the only cohort of MDR-TB patients treated with a fully
standardized regimen on ambulatory basis gave discouraging
results, with only 57% of the patients being cured [17]. This sub-
optimal outcome was probably due to the weak composition of the
treatment regimen, designed without taking into proper consid-
eration the underling resistance patterns to first- and second-line
drugs in the population. In Nepal a well conducted nationwide
drug resistance survey [9,10] provided population level data on
patterns of drug resistance that have been used to design a strong
standardized regimen for MDR-TB which could be entirely
delivered in outpatient facilities.
An individualized treatment regimen for MDR-TB would likely
not have worked in our setting. The lack of experienced health
workers on MDR-TB management and the long distances
between TB treatment centers would not have made possible
the expansion of MDR-TB services had it not been for the
utilization of a fully standardized regimen. The utilization of a
standardized regimen makes training, drug forecasting, and
management of adverse events much easier, in addition to
reducing significantly the overall cost of treatment [18].
Table 4. Major adverse events registered in the study cohort.
Adverse events No. of Patients %
Nausea/Vomiting 80 64.0
Diarrhoea 1 0.8
Arthralgia 90 72.0
Dizziness/vertigo 12 9.6
Hearing disturbance 12 9.6
Visual disturbances 6 4.8
Hypothyroidism 1 0.8
Sleep disturbances and minor mood changes 12 9.6
Depression 7 5.6
Suicidal thoughts 7 5.6
Psychosis 4 3.2
Rash 17 13.6
Jaundice 5 4.0
Seizures 0 0.0
Gynaecomastia 4 3.2
doi:10.1371/journal.pone.0008313.t004
Table 5. Variables associated with cure.
Bivariate analysis Multivariable analysis
Crude OR 95% CL Adjusted OR 95% CL
Sex
Male 1.0 Ref. 1.0 Ref
Female 1.0 0.5–2.1 1.6 0.7–3.7
Age-group (y)
14–24 1.6 0.6–4.2 2.1 0.7–6.6
25–34 1.2 0.5–2.7 1.6 0.6–4.3
35–44 1.0 0.3–3.0 1.1 0.3–3.8
45–69 1.0 Ref. 1.0 Ref.
Body weight (kg)
21–35 1.0 Ref. 1.0 Ref.
36–44 4.4 1.2–15.6 5.2 1.4–19.5
45–54 7.3 2.0–26.8 10.8 2.8–41.4
55–75 9.1 1.9–42.6 15.9 3.5–72.7
Region
Eastern 1.0 Ref. 1.0 Ref.
Central 5.1 1.8–14.2 7.2 2.4–21.3
Far-western 2.7 0.5–15.6 4.6 0.7–28.1
Mid-western 22.8 1.5–340.0 31.2 3.2–307.5
Western 2.4 0.7–9.0 2.4 0.6–9.4
Previous history
Category 2 failure 1.0 Ref. 1.0 Ref.
Category 1 failure 1.0 0.2–3.9 0.3 0.1–1.1
New case 0.8 0.1–9.5
Not specified 0.8 0.2–3.5
doi:10.1371/journal.pone.0008313.t005
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failures (87%), and there was no recruiting among previously
untreated TB patients (except family contacts). The strict
application of the enrolment criteria has made possible to use a
standardized treatment regimen throughout the country.
Despite decentralization of the services in ambulatories in
several regions overall default rates are quite high, but in line with
previous publications from countries implementing similar pro-
grams [19]. Unfavorable outcomes are not evenly distributed
across different areas of the country (Figure 2). The sub-optimal
outcomes in the Eastern region is a result of poor performance at
the NATA clinic in the region, which has a greater proportion of
defaulters. The large majority of them interrupt treatment within
the first six months from treatment start and after sputum and
culture conversion (data not shown) when they start feeling better.
The NATA clinic serves a very large catchment area and more
MDR-TB clinics have been recently opened in that area to
improve access to services in the most remote areas. In addition, to
encourage adherence to treatment, monetary incentives for
patients showing to take treatment regularly have been made
available by the programme. It will be interesting to evaluate the
effect of these incentives on default rates in the near future.
As expected, patients with low body weight have significantly
higher rates of death than those weighing more. In this cohort the
higher the body weight the greater was the chance of being cured
(Table 5). These findings are in line with previous publications
showing that undernourished patients with MDR-TB have greater
risk of unfavorable treatment outcomes [20] and that malnutrition
is an important risk factor for the development of TB [21]. In this
cohort the correlation between body weight and cure rate is very
strong. Food incentives and extra support should definitely be
considered for MDR-TB patients weighting less than 36 Kg.
Adverse events were managed by local health workers using a
standardized protocol based on the WHO guidelines [11,22].
Monitoring of potassium and creatinine was carried out on
monthly basis during the initial phase on treatment. In cases of low
potassium, magnesium was also checked. Renal and hepatic
functions were monitored only on the basis of symptoms. Type
and frequencies of adverse events reported in this study don’t differ
from what previously reported on similar cohorts of patients [23].
A total of 8 patients had disease caused by NTM strains
(Table 1) and ended up being treated with the standardized
treatment regimen for MDR-TB used in the country given the
absence of an alternative therapy. As expected the overall
treatment outcomes have been poor. Only the 2 patients infected
with M.fortuitum were cured. The remaining 6 patients (5 infected
with M.intracellulare and 1 with M.avium) defaulted. The proportion
of patients with NTM that end up being treated with regimens for
MDR-TB might not be negligible in resource-limited settings.
International guidelines on how to treat these patients are urgently
needed. For the moment guidance documents have been produced
by some medical societies [24].
One limitation of this study is that, due to lack of access to
routine DST for second-line drugs, XDR-TB cases could not be
detected at the start of MDR-TB treatment. Undiagnosed XDR-
TB may therefore be the cause of death of treatment failure in
some of the patients in this cohort. XDR-TB is though to be
present in around 7% of the patients enrolled in the MDR-TB
treatment programme in Nepal. Recently DST for key second-line
drugs has become more available and there are plans in Nepal to
make it available to all patients with confirmed MDR-TB.
The experience from the first year of the MDR-TB treatment
programme in Nepal shows that fully standardized treatment for
MDR-TB delivered through a network of outpatient facilities is
not only feasible but can also yield high cure rates in resource-
limited settings.
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